A detailed history of Candriam S.C.A. transactions in Cytokinetics Inc stock. As of the latest transaction made, Candriam S.C.A. holds 179,200 shares of CYTK stock, worth $9.8 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
179,200
Previous 179,200 -0.0%
Holding current value
$9.8 Million
Previous $9.71 Million 2.55%
% of portfolio
0.06%
Previous 0.06%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

SELL
$47.86 - $75.05 $15 Million - $23.6 Million
-313,829 Reduced 63.65%
179,200 $9.71 Million
Q1 2024

May 03, 2024

BUY
$63.75 - $108.06 $14.4 Million - $24.4 Million
225,789 Added 84.49%
493,029 $34.6 Million
Q4 2023

Feb 14, 2024

SELL
$26.88 - $83.49 $6.34 Million - $19.7 Million
-236,000 Reduced 46.9%
267,240 $22.3 Million
Q3 2023

Nov 13, 2023

SELL
$29.46 - $36.61 $1.03 Million - $1.28 Million
-35,000 Reduced 6.5%
503,240 $14.8 Million
Q1 2023

May 12, 2023

BUY
$33.36 - $45.71 $1.17 Million - $1.6 Million
35,000 Added 6.95%
538,240 $18.9 Million
Q3 2022

Nov 10, 2022

SELL
$38.54 - $54.52 $664,275 - $939,706
-17,236 Reduced 3.31%
503,240 $24.4 Million
Q2 2022

Aug 03, 2022

SELL
$33.93 - $48.92 $4.06 Million - $5.86 Million
-119,752 Reduced 18.7%
520,476 $20.4 Million
Q1 2022

May 13, 2022

BUY
$29.74 - $46.0 $3.77 Million - $5.84 Million
126,884 Added 24.72%
640,228 $23.6 Million
Q2 2021

Jul 20, 2021

BUY
$19.79 - $26.99 $2.72 Million - $3.71 Million
137,491 Added 36.58%
513,344 $10.2 Million
Q4 2020

Jan 22, 2021

BUY
$15.26 - $28.61 $3.6 Million - $6.74 Million
235,628 Added 168.04%
375,853 $7.81 Million
Q3 2020

Oct 19, 2020

BUY
$20.58 - $28.96 $2.89 Million - $4.06 Million
140,225 New
140,225 $3.04 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $5.15B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.